Back to top
more

Axsome Therapeutics (AXSM)

(Delayed Data from NSDQ)

$90.07 USD

90.07
635,290

-0.63 (-0.69%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $90.16 +0.09 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study

by Zacks Equity Research

Axsome's (AXSM) AXS-05 meets key secondary endpoints in late-stage study for addressing patients with treatment resistant depression. However, the primary endpoint did not reach statistical significance.

Axsome Expedites Completion Timeline of AD Study on AXS-05

by Zacks Equity Research

Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.

Is the Options Market Predicting a Spike in Axsome Therapeutics (AXSM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

What's in Store for Axsome (AXSM) This Earnings Season?

by Zacks Equity Research

On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Axsome Therapeutics (AXSM) closed at $87.60 in the latest trading session, marking a +0.72% move from the prior day.

Axsome (AXSM) Completes Patient Randomization in TRD Study

by Zacks Equity Research

Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.

ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why

by Zacks Equity Research

ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.

Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

The Zacks Analyst Blog Highlights: Cirrus Logic, CIRCOR, Axsome and Digital Turbine

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Cirrus Logic, CIRCOR, Axsome and Digital Turbine

Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study

by Zacks Equity Research

Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.

Sweta Killa headshot

Top 2019 Wall Street Stories That May Hit Headlines in 2020

by Sweta Killa

We discuss some of the events that dominated the headlines in 2019 and influenced the market.

Sanghamitra Saha headshot

Biotech Rally Sends Nasdaq to 9000: ETFs in Focus

by Sanghamitra Saha

Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.

Sweta Killa headshot

Biotech Leading in Q4: Best ETFs & Stocks

by Sweta Killa

We highlight five biotech ETFs and stocks that are leading the market in Q4.

Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

by Zacks Equity Research

Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

Implied Volatility Surging for Axsome (AXSM) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

Axsome (AXSM) Catches Eye: Stock Jumps 9.3%

by Zacks Equity Research

Axsome (AXSM) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Axsome (AXSM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

Implied Volatility Surging for Axsome (AXSM) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

Axsome Initiates Phase III Study on Depression Candidate

by Zacks Equity Research

Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.

What's in the Cards for Fuel Tech (FTEK) in Q1 Earnings?

by Zacks Equity Research

Fuel Tech's (FTEK) Q1 results are likely to benefit from increased adoption of emission control solutions, efforts to improve sales channel and addition of a coal-fired unit in the United States.

What's in Store for Axsome (AXSM) This Earnings Season?

by Zacks Equity Research

On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

by Zacks Equity Research

Key highlights of the past week are collaborations and pipeline updates.

Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up

by Zacks Equity Research

Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.